… erlotinib and gefitinib in clinical practice. Type of TK inhibitors did not influence treatment
outcomes in patients with EGFR mutation or wild-type EGFR. … EGFR TKIs in patients with EGFR …

… EGFR TKI therapy against chemotherapy or placebo. We extracted data from the EGFR TKI
… ) adverse events (AEs), and discontinuation of treatment because of AE for each EGFR TKI. …

… EGFR-tyrosine kinase inhibitor (TKI) shows a durable response against NSCLC harboring
EGFR … following first-line EGFR-TKIs [first- and second-generation (G) TKIs]. When resistant …

… EGFR TKIs, ie., gefitinib monotherapy, erlotinib monotherapy, afatinib monotherapy, or any
two of them, in NSCLC patients and reported results on at least one of the following outcomes…

… The biological activity was associated with the potential difference in tumor sensitivity of
EGFR TKIs. The pharmacokinetic data was in good agreement with the efficacious rankings …

… EGFR-TKIs comes from a limited number of retrospective studies comparing gefitinib, erlotinib,
… Resistance to EGFR TKIs therapy has been associated with a Thr790Met substitution in …

… In recent years, this led to the emergence of a new class of agents, the tyrosine kinase
inhibitors (TKIs). Two small-molecule EGFR TKIs, gefitinib (Iressa™) and erlotinib (Tarceva™), …

… to EGFR-TKI was 71.1% (n = 207), and from the EGFR TKI arm … to EGFR-TKI was 77.2% (n
= 166), and from the EGFR TKI … There were more patients in the EGFR-TKI arm who received …

… sensitive EGFR mutations. The first-generation EGFR-TKIs included icotinib, erlotinib and
gefitinib… EGFR-TKIs in advanced NSCLC patients harboring EGFR mutations (13). However, in …

… of the power of EGFR TKIs in patients with EGFR mutations: a historical … gefitinib approval
in Japan, in conjunction with EGFR mutational status, overall survival of patients with EGFR …